Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 5
2000 2
2002 1
2003 4
2004 4
2005 9
2006 12
2007 9
2008 9
2009 10
2010 4
2011 12
2012 14
2013 14
2014 9
2015 14
2016 22
2017 28
2018 31
2019 31
2020 40
2021 41
2022 43
2023 36
2024 52
2025 74
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Results by year

Filters applied: . Clear all
Page 1
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
Cui J, Qin S, Zhou Y, Zhang S, Sun X, Zhang M, Cui J, Fang W, Gu K, Li Z, Wang J, Chen X, Yao J, Zhou J, Wang G, Bai Y, Xiao J, Qiu W, Wang B, Xia T, Wang C, Kong L, Yin J, Zhang T, Shen X, Fu D, Gao C, Wang H, Wang Q, Wang L. Cui J, et al. Signal Transduct Target Ther. 2024 Sep 19;9(1):248. doi: 10.1038/s41392-024-01948-4. Signal Transduct Target Ther. 2024. PMID: 39300077 Free PMC article. Clinical Trial.
Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-controlled, multicenter phase 3 …
Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocar …
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. Wang-Gillam A, et al. Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654298 Free article. Clinical Trial.
BACKGROUND: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. ...RESULTS: The overall survival advantage fo …
BACKGROUND: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastat …
Irinotecan Liposome Injection.
Baker DE, Levien TL. Baker DE, et al. Hosp Pharm. 2017 Feb;52(2):144-150. doi: 10.1310/hpj5202-144. Hosp Pharm. 2017. PMID: 28321142 Free PMC article.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.
A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. ...FINDINGS: Between Jan 11, 2012, and Sept 11, 2013, 417 …
A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil …
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Kciuk M, Marciniak B, Kontek R. Kciuk M, et al. Int J Mol Sci. 2020 Jul 12;21(14):4919. doi: 10.3390/ijms21144919. Int J Mol Sci. 2020. PMID: 32664667 Free PMC article. Review.
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. ...Here, we give a comprehensive overview on irinotecan's molecular mode of action, metabolism, pharmacogenetics, and toxi …
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expandi …
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G, Innocenti F, Minami H. Milano G, et al. Cancer Sci. 2022 Jul;113(7):2224-2231. doi: 10.1111/cas.15377. Epub 2022 May 26. Cancer Sci. 2022. PMID: 35445479 Free PMC article. Review.
Liposomal irinotecan also has a longer half-life and higher area under the concentration-time curve (0-) than nonliposomal irinotecan, as the liposomal formulation protects cargo from premature metabolism in the plasma. ...Liposomal irinoteca …
Liposomal irinotecan also has a longer half-life and higher area under the concentration-time curve (0-) than nonliposomal …
Irinotecan: 25 years of cancer treatment.
Bailly C. Bailly C. Pharmacol Res. 2019 Oct;148:104398. doi: 10.1016/j.phrs.2019.104398. Epub 2019 Aug 12. Pharmacol Res. 2019. PMID: 31415916 Review.
Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the treatment of cancer. For more than two decades, the IRT prodrug has largely contributed to the treatment of solid tumors worldwide. ...This review highlights recent discoveries i …
Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the treatment of cancer. For more than two …
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. Wainberg ZA, et al. Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11. Lancet. 2023. PMID: 37708904 Free PMC article. Clinical Trial.
Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX (liposomal irinotecan 50 mg/m(2), oxaliplatin 60 mg/m(2), leucovorin 400 mg/m(2), and fluorouracil 2400 mg/m(2), administered …
Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX …
Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.
Li X, Zhang C, Mei Y, Zhong W, Fan W, Liu L, Feng Z, Bai X, Liu C, Xiao M, He W, Lin T, Gou X. Li X, et al. Signal Transduct Target Ther. 2025 Jul 10;10(1):214. doi: 10.1038/s41392-025-02302-y. Signal Transduct Target Ther. 2025. PMID: 40634292 Free PMC article. Clinical Trial.
A single-arm, phase I study (identifier NCT06766266) initiated by us suggested that the combination of irinotecan liposomes plus EPI is a feasible and safe treatment strategy for patients with anthracycline-resistant bladder cancer who experience recurrence. These f …
A single-arm, phase I study (identifier NCT06766266) initiated by us suggested that the combination of irinotecan liposomes pl …
Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A, Pommier Y. Thomas A, et al. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. doi: 10.1158/1078-0432.CCR-19-1089. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227499 Free PMC article. Review.
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years. ...We introduce new therapeutic strategies based on novel TOP1 inhibitor chemical scaffolds including the indenoisoquinolines LMP400 (indotecan), LMP776 (indimitecan), and LMP744, and …
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years. ...We introduce new therapeutic strategies …
477 results